Cargando…

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance

BACKGROUND: Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-like cysteine protease (3CL(pro)) inhibitors which have been approved for the treatment of COVID-19 in 2021 and 2022, respectively. Previous studies have identified 3CL(pro) mutations that are associated with reduced su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ip, Jonathan Daniel, Wing-Ho Chu, Allen, Chan, Wan-Mui, Cheuk-Ying Leung, Rhoda, Umer Abdullah, Syed Muhammad, Sun, Yanni, Kai-Wang To, Kelvin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101811/ https://www.ncbi.nlm.nih.gov/pubmed/37060743 http://dx.doi.org/10.1016/j.ebiom.2023.104559

Ejemplares similares

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
por: Kawashima, Sho, et al.
Publicado: (2023)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
por: Fukao, Keita, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

Evaluation of simple nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits
por: Chu, Allen Wing-Ho, et al.
Publicado: (2020)

The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms
por: Ramos-Guzmán, Carlos A., et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
por: Ishibashi, Toru, et al.
Publicado: (2023)

A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir
por: Vankadara, Subramanyam, et al.
Publicado: (2022)

Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir
por: Preschel, H. Daniel, et al.
Publicado: (2023)

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir
por: Kawajiri, Takahiro, et al.
Publicado: (2023)

Risk Factors for Slow Viral Decline in COVID-19 Patients during the 2022 Omicron Wave
por: Li, Xin, et al.
Publicado: (2022)

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
por: Ullrich, Sven, et al.
Publicado: (2022)

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
por: Toussi, Sima S., et al.
Publicado: (2022)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Development and Validation of a Novel COVID-19 nsp8 One-Tube RT-LAMP-CRISPR Assay for SARS-CoV-2 Diagnosis
por: Yip, Cyril Chik-Yan, et al.
Publicado: (2022)

Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
por: Paciaroni, Alessandro, et al.
Publicado: (2023)

The Remarkable Selectivity of Nirmatrelvir
por: Duveau, Damien Y., et al.
Publicado: (2022)

Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
por: Yang, Yujian, et al.
Publicado: (2023)

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
por: Hu, Yanmei, et al.
Publicado: (2022)

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
por: Hu, Yanmei, et al.
Publicado: (2023)

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
por: Citarella, Andrea, et al.
Publicado: (2023)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes
por: Padhi, Aditya K., et al.
Publicado: (2022)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir wirkt auch gegen Omikron
por: Gesierich, Wolfgang
Publicado: (2023)

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

537. Safety and Effectiveness of Ensitrelvir for the Treatment of COVID-19 in Japanese Clinical Practice: A Post-marketing Surveillance (Interim Analysis)
por: Ogura, Eriko, et al.
Publicado: (2023)

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
por: Brewitz, Lennart, et al.
Publicado: (2023)

Small change for big improvement in the preparation of the key intermediate N(1), N(3)-disubstituted 1,3,5-triazone of ensitrelvir
por: Hu, Wei, et al.
Publicado: (2023)

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection
por: Tsuge, Yuko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_84872f5a1t43rob7v02d8bqpjh